@coffeecup33
The fact that MSB didn't immediately tell us about the details of the equity financing facility that had been offered to them tells us that there are probably unfavourable terms inside it and that if the details are immediately released, it would put more downward pressure on the already weak share price.
Maybe Silviu was hoping that after the initial drop post trading halt, the share price would rally back to a level above $1.92 before releasing the details of the financing facility. This way, he couldn't be accused of diluting existing holders by issuing new shares at near 10-year low levels.
If the terms of the financing facility are favourable to MSB or if there is nothing nasty to hide, why couldn't they just release the details at the same time as the announcement of Teva walking away?
It simply doesn't make sense.
(20min delay)